Matribhumi Samachar English
Ad hoc announcement pursuant to Art. 53 LR 1,465 patients were randomized into the two identical-in-design clinical studies Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805) Both studies reached statistically significant endpoints in TAHC (Target-Area Hair Count), with one reaching 539% relative improvement to placebo and the second study reaching 168% …
Read More »Cosmo Pharmaceuticals Announces Regulatory Approval of Winlevi(R) in South Korea
Dublin, Ireland–(Newsfile Corp. – October 7, 2025) – Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has approved Winlevi® (clascoterone) cream 1% for the treatment of acne vulgaris …
Read More »Cosmo Appoints Federico Sommariva as Chief Legal Counsel
Dublin, Ireland–(Newsfile Corp. – April 1, 2025) – Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the appointment of Federico Sommariva ad Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in …
Read More »Cosmo Pharmaceuticals publishes Annual Report 2024
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland–(Newsfile Corp. – March 21, 2025) – Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) has published today its Annual Report for the fiscal year ending December 31, 2024. As already outlined in the unaudited 2024 Full-Year results on March 6, …
Read More »Cosmo Pharmaceuticals Delivers Record 2024 Results – Completes Phase III Enrollment for Androgenetic Alopecia in Males – Proposes Increased Dividend of 2.05 per share – Reinforcing Shareholder Value and Growth Momentum into 2025
Ad hoc announcement pursuant to Art. 53 LR FY 2024 Revenue of €266.8 million (unaudited) reaching upper end of guidance FY 2024 Operating Profit (unaudited) of €148.9 million, exceeding guidance, when adjusted for an accounting policy change Outlook for 2025 Dublin, Ireland–(Newsfile Corp. – March 6, 2025) – Cosmo Pharmaceuticals …
Read More »Cosmo to Host Investor Day on April 9, 2025
Dublin, Ireland–(Newsfile Corp. – February 12, 2025) – Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is pleased to announce that it will host an Investor Day on Wednesday, April 9, 2025. The live event will be held at the Hotel “Park Hyatt” at Beethovenstrasse 21 in 8002 Zurich, Switzerland. …
Read More »Cosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Across Portfolio
Dublin, Ireland–(Newsfile Corp. – February 11, 2025) – Planet Friendly Technologies, Inc.Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo’s commitment to integrating Artificial Intelligence as a core strategic pillar in its future …
Read More »Cosmo and Glenmark Announces UK MHRA Approval of Winlevi(R) for Treatment of Acne
Dublin, Ireland and Mumbai, India and London, United Kingdom–(Newsfile Corp. – February 10, 2025) – Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) and Glenmark Pharmaceuticals Limited (Glenmark), a global research-led pharmaceutical company, today announced that Glenmark had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to …
Read More »Invitation to Cosmo’s Unaudited Full Year 2024 Financial Results Webcast on 6 March 2025
Dublin, Ireland–(Newsfile Corp. – January 28, 2025) – Cosmo Pharmaceuticals N.V. (SIX: COPN: C43) (“Cosmo”) announced today that it will publish its unaudited Full-Year 2024 results on Thursday, 6 March 2025 at 7:00 am CET. Live conference call and video webcast presentation: Cosmo invites investors, financial analysts and business/life sciences …
Read More »